Medpace Holdings, Inc. (MEDP)

MEDP Income Statement

Revenue, expenses, and profitability analysis

MEDP Quarterly Income Statement (USD)

Quarterly Report	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025	12/31/2024	09/30/2024	06/30/2024
Revenue	2.678B	706.604M	708.450M	659.903M	603.311M	558.570M	536.589M	533.317M	528.104M
Cost of Goods Sold	1.900B	510.278M	503.134M	462.964M	423.298M	380.220M	358.272M	364.309M	374.266M
Gross Profit	778.594M	196.326M	205.316M	196.939M	180.013M	178.350M	178.317M	169.008M	153.838M
Gross Profit Margin	27.8%	27.8%	29.0%	29.8%	29.8%	31.9%	33.2%	31.7%	29.1%
Total Operating Expenses	215.679M	54.823M	52.047M	55.131M	53.678M	64.827M	52.939M	56.735M	48.688M
Research & Development	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling, General & Administrative	187.579M	47.917M	44.916M	48.082M	46.664M	57.897M	45.433M	49.217M	41.453M
Operating Income (EBIT)	562.915M	141.503M	153.269M	141.808M	126.335M	113.523M	125.378M	112.273M	105.150M
Operating Margin	20.0%	20.0%	21.6%	21.5%	20.9%	20.3%	23.4%	21.1%	19.9%
Income Before Tax (EBT)	571.798M	147.591M	156.833M	142.836M	124.538M	118.170M	133.882M	118.776M	110.482M
Interest Income	7.712M	5.117M	—	1.517M	1.078M	6.463M	7.883M	7.528M	5.465M
Interest Expense	—	—	—	—	—	—	—	—	—
Other Income/Expense	8.883M	6.088M	3.564M	1.028M	-1.797M	4.647M	8.504M	6.503M	5.332M
Net Income	460.398M	123.870M	135.133M	111.135M	90.260M	114.595M	117.018M	96.426M	88.351M
Income Tax Expense	111.400M	23.721M	21.700M	31.701M	34.278M	3.575M	16.864M	22.350M	22.131M
Net Profit Margin	17.5%	17.5%	19.1%	16.8%	15.0%	20.5%	21.8%	18.1%	16.7%
EBITDA	599.898M	154.497M	163.964M	149.885M	131.552M	125.100M	141.388M	126.294M	117.717M
EBITDA Margin	21.9%	21.9%	23.1%	22.7%	21.8%	22.4%	26.3%	23.7%	22.3%
Depreciation & Amortization	28.100M	6.906M	7.131M	7.049M	7.014M	6.930M	7.506M	7.518M	7.235M
EPS Basic	16.24	4.35	4.78	3.95	3.16	3.77	3.78	3.11	2.85
EPS Diluted	15.92	4.28	4.67	3.87	3.10	3.67	3.67	3.01	2.75
Shares Outstanding	28.445M	28.445M	28.291M	29.033M	29.489M	30.387M	30.945M	31.047M	30.990M
Diluted Shares Outstanding	28.962M	28.962M	28.964M	29.710M	30.165M	31.196M	32.014M	32.088M	32.086M

MEDP Annual Income Statement (USD)

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	2.530B	2.109B	1.886B	1.460B	1.142B	925.925M	860.969M	704.589M
Cost of Goods Sold	1.770B	1.453B	1.361B	1.028B	814.222M	647.199M	615.272M	489.059M
Gross Profit	760.618M	656.305M	524.505M	432.438M	328.155M	278.726M	245.697M	215.530M
Gross Profit Margin	30.1%	31.1%	27.8%	29.6%	28.7%	30.1%	28.5%	30.6%
Total Operating Expenses	225.683M	209.435M	187.680M	153.741M	129.540M	111.684M	118.434M	114.482M
Research & Development	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling, General & Administrative	197.559M	180.184M	161.352M	131.400M	108.421M	92.156M	95.245M	75.681M
Operating Income (EBIT)	534.935M	446.870M	336.825M	278.697M	198.615M	167.042M	127.263M	101.048M
Operating Margin	21.1%	21.2%	17.9%	19.1%	17.4%	18.0%	14.8%	14.3%
Income Before Tax (EBT)	542.377M	475.922M	335.682M	282.860M	201.852M	168.532M	124.832M	93.951M
Interest Income	—	24.996M	—	—	—	307K	—	—
Interest Expense	—	—	488K	2.905M	105K	—	1.568M	8.157M
Other Income/Expense	7.442M	29.052M	-1.143M	4.163M	3.237M	1.490M	-2.431M	-7.097M
Net Income	451.123M	404.386M	282.810M	245.368M	181.848M	145.384M	100.443M	73.185M
Income Tax Expense	91.254M	71.536M	52.872M	37.492M	20.004M	23.148M	24.389M	20.766M
Net Profit Margin	17.8%	19.2%	15.0%	16.8%	15.9%	15.7%	11.7%	10.4%
EBITDA	570.501M	505.173M	362.498M	308.106M	223.076M	186.570M	150.452M	139.849M
EBITDA Margin	22.5%	24.0%	19.2%	21.1%	19.5%	20.1%	17.5%	19.8%
Depreciation & Amortization	28.124M	29.251M	26.328M	22.341M	21.119M	19.528M	23.189M	38.801M
EPS Basic	15.64	13.06	9.20	7.57	5.06	4.07	2.79	2.05
EPS Diluted	15.28	12.63	8.88	7.28	4.81	3.84	2.67	1.97
Shares Outstanding	28.846M	30.957M	30.722M	32.388M	35.862M	35.635M	35.881M	35.547M
Diluted Shares Outstanding	29.527M	32.014M	31.841M	33.671M	37.697M	37.708M	37.576M	36.912M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Medpace Holdings, Inc.

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

Cincinnati, OH

5,900 employees

www.medpace.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: August James Troendle

View full financials